Bausch + Lomb (BLCO) Projected to Post Quarterly Earnings on Wednesday

Bausch + Lomb (NYSE:BLCO - Get Free Report) is expected to announce its Q2 2025 earnings results before the market opens on Wednesday, July 30th. Analysts expect the company to announce earnings of $0.07 per share and revenue of $1.25 billion for the quarter. Bausch + Lomb has set its FY 2025 guidance at EPS.

Bausch + Lomb (NYSE:BLCO - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.03 by ($0.10). The firm had revenue of $1.15 billion for the quarter, compared to analysts' expectations of $1.15 billion. Bausch + Lomb had a positive return on equity of 2.62% and a negative net margin of 7.50%. Bausch + Lomb's revenue was up 3.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.07 earnings per share. On average, analysts expect Bausch + Lomb to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Bausch + Lomb Stock Up 2.0%

BLCO traded up $0.28 during mid-day trading on Friday, reaching $14.25. 1,755,751 shares of the stock were exchanged, compared to its average volume of 775,715. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.96 and a current ratio of 1.56. The stock has a market capitalization of $5.04 billion, a PE ratio of -13.84, a price-to-earnings-growth ratio of 1.57 and a beta of 0.62. The company has a 50 day moving average price of $12.64 and a two-hundred day moving average price of $14.04. Bausch + Lomb has a 1 year low of $10.45 and a 1 year high of $21.69.

Insider Activity at Bausch + Lomb

In other Bausch + Lomb news, CEO Brent L. Saunders acquired 22,000 shares of the business's stock in a transaction dated Thursday, May 22nd. The stock was bought at an average price of $11.28 per share, with a total value of $248,160.00. Following the completion of the acquisition, the chief executive officer owned 719,156 shares of the company's stock, valued at $8,112,079.68. This trade represents a 3.16% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 0.76% of the company's stock.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Bausch + Lomb stock. Woodline Partners LP raised its holdings in shares of Bausch + Lomb Corporation (NYSE:BLCO - Free Report) by 0.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 312,823 shares of the company's stock after acquiring an additional 1,436 shares during the period. Woodline Partners LP owned about 0.09% of Bausch + Lomb worth $4,536,000 at the end of the most recent reporting period. 11.07% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have issued reports on BLCO shares. Stifel Nicolaus cut their price objective on shares of Bausch + Lomb from $17.00 to $15.00 and set a "hold" rating on the stock in a report on Thursday, April 3rd. Wells Fargo & Company lowered their target price on Bausch + Lomb from $15.00 to $12.00 and set an "equal weight" rating on the stock in a research note on Thursday, May 1st. Barclays lowered their target price on Bausch + Lomb from $19.00 to $16.00 and set an "equal weight" rating on the stock in a research note on Monday, June 9th. HC Wainwright lowered their target price on Bausch + Lomb from $20.00 to $15.00 and set a "buy" rating on the stock in a research note on Friday, May 2nd. Finally, Citigroup lifted their target price on Bausch + Lomb from $13.00 to $15.00 and gave the stock a "neutral" rating in a research note on Wednesday, July 9th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and three have issued a buy rating to the company's stock. According to data from MarketBeat.com, Bausch + Lomb has a consensus rating of "Hold" and a consensus price target of $15.45.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.